Aclaris Therapeutics ATI-052 Phase 1a Trial Results and ATI-2138 Lead Indication Update Set for April 28, 2026

Key Takeaways

• Aclaris will release complete Phase 1a trial data for ATI-052, an anti-TSLP/IL-4R bispecific antibody targeting immuno-inflammatory diseases
• The company will announce lead indication selection for ATI-2138, an oral ITK/JAK3 inhibitor with potential applications across multiple conditions
• Clinical updates scheduled for April 28, 2026, could influence Aclaris’s development strategy and market positioning in the competitive immunology space

---

WAYNE, Pa. – April 27, 2026 – Aclaris Therapeutics, Inc. (NASDAQ: ACRS) will provide comprehensive clinical updates on two key pipeline assets on April 28, 2026, including full Phase 1a trial results for its bispecific antibody ATI-052 and lead indication selection for oral inhibitor ATI-2138.

ATI-052 Bispecific Antibody Shows Promise

The clinical-stage biopharmaceutical company will release complete data from ATI-052’s Phase 1a single and multiple ascending dose trial. ATI-052 represents an innovative anti-TSLP/IL-4R bispecific antibody designed to simultaneously target two critical pathways in immuno-inflammatory diseases.

Bispecific antibodies like ATI-052 offer potential advantages over single-target therapies by blocking multiple disease mechanisms simultaneously, potentially improving efficacy while reducing treatment burden for patients with conditions such as atopic dermatitis, asthma, and other allergic diseases.

IntelligenceRegulatory Impact▾

FDA set GMP, data-integrity, and post-approval change expectations for sterile and biologics manufacturing in the Americas. Regulatory relevance reads medium for pharmaceutical intelligence. Track inspection trends, Annex 1 alignment, and submission pathways for continuous manufacturing.

ATI-2138 Oral Inhibitor Advances

Aclaris will also announce results from its lead indication selection process for ATI-2138, an oral ITK/JAK3 inhibitor. This dual-mechanism approach targets both interleukin-2-inducible T-cell kinase (ITK) and Janus kinase 3 (JAK3), key enzymes involved in immune cell signaling.

Oral inhibitors like ATI-2138 offer convenience advantages over injectable biologics, potentially improving patient compliance and expanding treatment accessibility across various immuno-inflammatory conditions.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low on capacity and tech-transfer positioning. Benchmark which CDMOs, equipment vendors, and sponsors adopt continuous and isolator platforms first. Supplier hub and pipeline links below connect to named partners.

Market Implications

The immunology market continues expanding rapidly, driven by increasing prevalence of autoimmune and inflammatory diseases. Aclaris’s dual-asset approach positions the company to compete in multiple therapeutic areas, from dermatology to rheumatology.

Investors and clinicians will closely monitor these updates for safety signals, efficacy trends, and competitive positioning against established treatments from companies like AbbVie, Johnson & Johnson, and Pfizer.

The April 28 presentation timing suggests Aclaris aims to provide transparency on clinical progress as the company advances these programs toward potential Phase 2 development.

---

Frequently Asked Questions

What makes ATI-052 different from existing treatments?

ATI-052 is a bispecific antibody that simultaneously targets both TSLP and IL-4R pathways, potentially offering superior efficacy compared to single-target therapies currently available for immuno-inflammatory diseases.

When will ATI-052 and ATI-2138 be available to patients?

Both drugs are in early clinical development. ATI-052 is completing Phase 1a trials, while ATI-2138 is in lead indication selection. Patient availability would likely be several years away, pending successful Phase 2 and Phase 3 trials plus regulatory approval.

How do these Aclaris drugs compare to current immunology treatments?

ATI-052’s bispecific design and ATI-2138’s oral formulation could offer advantages over existing injectable biologics in terms of efficacy, convenience, and patient compliance, though clinical trial results will determine their competitive positioning.

Related coverage

• Novo Nordisk CagriSema Phase 3 Results: Obesity Catalyst Update
• Nektar Therapeutics pipeline update: REZPEG, amphotericin B and UK site changes
• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial